药物去势联合雄激素受体阻断剂治疗晚期前列腺癌(附5年临床观察)  

Medical castration plus flutamide for the treatment of local advanced and metastatic prostate cancer

作　　者：孙忠全[1] 钱伟庆[1] 宋建达[1] 林兴[1] 

机构地区：[1]上海华东医院泌尿外科,上海200040

出　　处：《中国男科学杂志》2003年第4期239-241,共3页Chinese Journal of Andrology

摘　　要：目的 观察药物去势联合雄激素受体阻断剂(氟硝丁酰胺,Flutmlide)治疗晚期前列腺癌的疗效及药物去势的稳定性。方法 回顾性分析35例药物去势加雄激素阻断剂治疗晚期前列腺癌的临床资料。结果 所有病人应用LHRH-A 1个月后血睾酮降至去势水平,持续给药可维持稳定的去势水平。34例有治疗效果,有效率97.1％。经平均38.4月随访,复发率为11.8％。7例出现肝功能异常,15例出现食欲减退,35例出现性欲减退和勃起障碍,2例出现血像异常,16例出现潮热、盗汗。结论 药物去势联合雄激素阻断剂治疗初发的晚期前列腺癌疗效肯定,去势稳定。Objective To evaluate the stability of medical castration and the efficacy of medical castration plus flutamide in the treatment of local advanced and metastatic prostate cancer. Methods 35 cases of local advanced and metastatic prostate cancer undergoing combination treatment were analyzed retrospectively. Results The patients with local advanced and metastatic prostate cancer were mean followed up for 38.4 months. In all patients serum testosterone decreased from normal to castrate level after one month treatment with LHRH analogues. Castrate level can be maintained as continued use of LHRH analogues. 34 cases achieved significant effects, effective rate was 97.1% and relapse rate was 11.8%. 7 showed impaired liver function, other side effects involved hyposexuality and erectile dysfunction, decreased food appetite, blood test disorder, hot flushs and night sweats. Conclusions Medical castration plus flutamide is effective for the management of local advanced and metastatic prostate cancer and can maintain stable castration level.

关 键 词：前列腺癌 药物去势 氟硝丁酰胺 

分 类 号：R737.25[医药卫生—肿瘤]